title: Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
abstract: Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
authors: Cancer Research UK Clinical Centre, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
authors: L
authors: L
authors: Nolan
authors: P W M
authors: PW
authors: Johnson
authors: A
authors: A
authors: Ganesan
authors: G
authors: G
authors: Packham
authors: S J
authors: SJ
authors: Crabb
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors